The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
David CampbellKen O'DayNadine HertelJohn R PenrodMelinda Manley DaumontMichael LeesPublished in: Population health metrics (2018)
Driven by growth in the incidence of NSCLC among women, the model forecasts an overall increase in the number of patients with advanced-stage squamous and non-squamous NSCLC likely to receive systemic treatment in the year 2020. The results highlight the significant burden of refractory advanced NSCLC and the need for more robust surveillance data to accurately quantify the burden of disease.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- small cell lung cancer
- high grade
- risk factors
- low grade
- public health
- polycystic ovary syndrome
- tyrosine kinase
- stem cells
- type diabetes
- mesenchymal stem cells
- pregnancy outcomes
- combination therapy
- machine learning
- adipose tissue
- data analysis
- cervical cancer screening